Home    Back

96. Crohn disease
2,209 clinical trials,   1,276 drugs   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
11 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1ChiCTR2000036845
2021-01-012020-08-25A single-center, randomized, controlled study on the effect of proactive therapeutic drug monitoring on the efficacy and cost of adamumab in the treatment of Crohn's diseaseA single-center, randomized, controlled study on the effect of proactive therapeutic drug monitoring on the efficacy and cost of adamumab in the treatment of Crohn's disease Crohn's diseaseProctive treatment drug monitoring group:In the proactive TDM group, adamumab is 160mg at week 0, 80mg at week 2, and 40mg once every two weeks from week 4 until week 8. Adalimumab serum trough concentration is going to be monitored at week 8, 16, 24, 32 and 40 after inclusion: 1.If serum trough concentration=11.7 g/ mL, continue&#;Reactive treatment drug monitoring group:In the reactive TDM group, adamumab is 160mg at week 0, 80mg at week 2, and 40mg once every two weeks from week 4 until week 8. Clinical response is assesed at week 8, 16, 24, 32, and 40 after inclusion: 1.If the clinical response is achieved, continue to administer 40mg once every ;Xinhua Hospital Affiliated to Shanghai Jiaotong University School of MedicineNULLPending1870BothProctive treatment drug monitoring group:60;Reactive treatment drug monitoring group:60;Phase 4China
2ChiCTR2000035737
2020-10-012020-08-16Application of indocyanine green fluorescence angiography in preventing anastomotic recurrence after Crohn’s disease intestinal resection and anastomosis: a single-center, prospective, randomized controlled trialApplication of indocyanine green fluorescence angiography in preventing anastomotic recurrence after Crohn’s disease intestinal resection and anastomosis: a single-center, prospective, randomized controlled trial Crohn's diseaseExperimental group:The scope of surgical resection was determined by indocyanine green fluorescence angiography;Control group:The scope of surgical resection (2cm away from the lesion site) determined by the physician based on experience;Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of MedicineNULLPending1870BothExperimental group:45;Control group:45;China
3JPRN-JapicCTI-205298
10/6/202026/05/2020A Study of Guselkumab in Participants with Moderately to Severely Active Crohn's DiseaseA Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease Crohn's DiseaseIntervention name : Guselkumab
INN of the intervention : Guselkumab
Dosage And administration of the intervention : Guselkumab will be administered intravenously for the first 3 doses and then subcutaneously for the subsequent doses.
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -		Janssen Pharmaceutical K.K.NULLpending18BOTH25Phase 3Japan
4ChiCTR2000031344
2020-05-012020-03-28Endoscopic Stricturotomy combined with local injection of bleomycin in the treatment of primary anorectal stricture in crohn's disease: a Prospective, double-blind, randomized controlled clinical studyEndoscopic Stricturotomy combined with local injection of bleomycin in the treatment of primary anorectal stricture in crohn's disease: a Prospective, double-blind, randomized controlled clinical study Crohn's diseaseGroup 1:Endoscopic Stricturotomy;Group 2:Endoscopic Stricturotomy combined with local bleomycin injection;The Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of MedicineNULLPendingBothGroup 1:35;Group 2:35;China
5ChiCTR2000029323
2020-03-012020-01-25Laparoscopic bowel resection combined with infliximab treatment versus infliximab for localized intestinal Crohn's disease: a randomized controlled, open-label trialLaparoscopic bowel resection combined with infliximab treatment versus infliximab for localized intestinal Crohn's disease: a randomized controlled, open-label trial Crohn's diseaseExperimental group:Laparoscopic bowel resection combined with postoperative Infliximab treatment;Control group:Infliximab;Renji Hospital, School of Medicine, Shanghai Jiaotong UniversityNULLPending1880BothExperimental group:30;Control group:30;China
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6ChiCTR1900026091
2019-09-192019-09-20Development of a predictive nomogram for primary non-response to infliximab in patients with Crhon's diseaseDevelopment of a predictive nomogram for primary non-response to infliximab in patients with Crhon's disease: a multicenter study Crohn's diseaseCase series:infliximab;The First Affiliated Hospital of Sun Yat-sen UniversityNULLPending958BothCase series:343;China
7ChiCTR1900023696
2019-07-012019-06-08Endoscopic balloon dilatation combined with local betamethasone injection to prevent recurrence of anastomotic stenosis after ileocolic resection for Crohn's disease: a single-center prospective randomized controlled trialEndoscopic balloon dilatation combined with local betamethasone injection to prevent recurrence of anastomotic stenosis after ileocolic resection for Crohn's disease: a single-center prospective randomized controlled trial Chron's diseaseGroup 1:EBD;Group 2:EBD combined with local injection of betamethasone;The Sixth Affiliated Hospital of Sun Yat-sen UniversityNULLPending1875BothGroup 1:45;Group 2:45;N/AChina
8JPRN-JapicCTI-194830
01/7/201927/06/2019Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]Specified Drug-Use Survey on Entyvio for IV Infusion 300 mg [Crohn's Disease] Crohn's diseaseIntervention name : Vedolizumab (Genetical Recombination)
INN of the intervention : Vedolizumab
Dosage And administration of the intervention : Vedolizumab (Genetical Recombination) 300 milligrams (mg), intravenous (IV) infusion, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care.
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -		Takeda Pharmaceutical Company LimitedNULLpendingBOTH300NAJapan
9ChiCTR1900022728
2019-05-012019-04-23Cohort study combined with omics screening for the early diagnostic markers in Crohn's diseaseCohort study combined with omics screening for the early diagnostic markers in Crohn's disease Crohn's diseaseGold Standard:Clinical outcome;Index test:Comprehensive serological markers, metabolomics, intestinal microbes, pathological features, imaging features of clinical subclinical CD, combined with clinical and endoscopic features, to explore early diagnosis of CD;The 7th Medical Center of the PLA General Hospital (Army general hospital)NULLPendingBothTarget condition:310;Difficult condition:160China
10ChiCTR1800015174
2018-05-012018-03-12Effects of Vitamin D supplementation on clinical prognosis for patients with Crohn's diseaseEffects of Vitamin D supplementation on clinical prognosis for patients with Crohn's disease Crohn's diseasecontrol group:placebo;Vitamin D:800IU Vitamin D;Gudangdong General Hospital, Guangdong Academy of Medical SciencesNULLPending1875Bothcontrol group:32;Vitamin D:32;China
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
11JPRN-UMIN000024566
2016/11/0101/11/2016Study on the selection of appropriate patients for the dose escalation of adalimumab in Crohn's disease therapy. Crohn'diseaseDose escalation group
Administration of Adalimumab 80 mg every other week

Non-dose escalation group
Administration of Adalimumab 40 mg every other week		Toho University Medical Center Sakura HospitalNULLPending16years-oldNot applicableMale and Female60Not applicableJapan

Back to top